Lantern Pharma stock climbs after LP-184 cancer drug hits trial endpoints
PositiveFinancial Markets

Lantern Pharma's stock has risen following successful trial results for its cancer drug LP-184. The drug met key endpoints, indicating potential effectiveness in treating certain cancers.
Editor’s Note: This development is significant as it suggests progress in cancer treatment options, which could lead to improved patient outcomes and potentially boost Lantern Pharma's market position.
— Curated by the World Pulse Now AI Editorial System